Skip to main content
Chandra Belani, MD, Oncology, Hershey, PA, Penn State Milton S. Hershey Medical Center

ChandraPBelaniMD

Oncology Hershey, PA

Professor of Medicine Penn State Milton S. Hershey Medical Center Deputy Director Penn State Cancer Institute

Dr. Belani is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Belani's full profile

Already have an account?

Education & Training

  • University of Maryland
    University of MarylandFellowship, Hematology and Medical Oncology, 1985 - 1988
  • Icahn School of Medicine at Mount Sinai (North General)
    Icahn School of Medicine at Mount Sinai (North General)Residency, Internal Medicine, 1984 - 1985
  • University of Maryland
    University of MarylandResidency, Internal Medicine, 1982 - 1984
  • Sawai Man Singh Medical College
    Sawai Man Singh Medical CollegeClass of 1977

Certifications & Licensure

  • MD State Medical License
    MD State Medical License 1984 - 2024
  • PA State Medical License
    PA State Medical License 1988 - 2024
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • America's Top Doctors Castle Connolly, 2002-2014
  • America's Top Doctors for Cancer Castle Connolly, 2005-2013
  • Pittsburgh Magazine Castle Connolly, 2005-2007

Clinical Trials

Publications & Presentations

PubMed

Lectures

  • Emerging Strategies in Treatment of Non−Small-Cell Lung Cancer and Head & Neck Cancer 2012 
    CancerNet, LLC, Atlanta, Georgia - 6/16/2012
  • 5th Symposium on Emerging Treatments & Advances in Novel Cancer Therapies for Practicing Physicians & Healthcare Professionals 
    CancerNet, LLC, Dallas, Texas - 1/18/2012

Press Mentions

  • Serplulimab First Anti-PD-1 to Improve Overall Survival in Extensive-Stage SCLC
    Serplulimab First Anti-PD-1 to Improve Overall Survival in Extensive-Stage SCLCJune 6th, 2022
  • Lung Cancer COVID-19 Guidance Available
    Lung Cancer COVID-19 Guidance AvailableJuly 23rd, 2020
  • International Association for the Study of Lung Cancer Appoints Chandra P. Belani, M.D. As New Chief Science Officer
    International Association for the Study of Lung Cancer Appoints Chandra P. Belani, M.D. As New Chief Science OfficerNovember 25th, 2019
  • Join now to see all

Grant Support

  • Clinical Trial: PI &Pharmacokinetic Study Of Drug For Solid Tumors &LymphomasNational Center For Research Resources2009
  • Clinical Trial: PI &Pharmacokinetic Single Agent Study Of Drug In PTS W Adv MaliNational Center For Research Resources2009
  • Clinical Trial: A Phase I Study In Advanced Solid Malignancies (Nci 7967)National Center For Research Resources2009
  • Phase I Clinical Trials Of Novel Anticancer AgentsNational Cancer Institute2003–2006
  • Adenovirus P53 Construct For Hepatocellular CarcinomaNational Center For Research Resources2000–2002
  • Filgrastim Sd/01 PTS W/ NON Small Cell Lung Cancer Or Thoracic TumorsNational Center For Research Resources1999–2002
  • Phase I Pharmacokinetic Study Of Carboplatin In Combo With Weekly PaclitaxelNational Center For Research Resources1998–2002
  • Filgrastim For Treatment Of Nonsmall Cell Lung Cancer Or Thoracic TumorsNational Center For Research Resources1999
  • Pharmacokinetic Study Of Taxol &Carboplatin With Filgrastim In Lung CarcinomaNational Center For Research Resources1997
  • Phase I Study Of Docetaxel And Carboplatin In Combination ChemotherapyNational Center For Research Resources1996–1997
  • Phase II Study Of IV Administered Tirapazamine PLUS Cisplatin In NsclcNational Center For Research Resources1996
  • Phase I/II Pharmacokinetic Study Of Taxol And Carboplatin With FilgrastimNational Center For Research Resources1996

Professional Memberships

Hospital Affiliations